Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
The SAD trial was designed to evaluate the safety and pharmacokinetics of COR588 in healthy volunteers.
In the SAD portion of the Phase 1 trial, preliminary results indicate COR588 was well-tolerated across all four cohorts in the dose range from 25 mg to 200 mg with no serious adverse events.
No clinically significant findings were observed on other safety measures, including vital signs, laboratory findings, telemetry, or ECGs.
COR588 exhibited an 11-to-12-hour half-life consistent with once-daily dosing and a dose-proportional pharmacokinetic profile.
The Company will share the complete data set from the COR588 Phase 1 trial in Q2 of 2022 once the multiple ascending dosing phase is complete.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.